Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Feb

Today In Oncology

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Preclinical Study Shows Losartan May Prevent Immune Checkpoint Inhibitor Induced Cerebral Edema in Glioblastoma

Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry

Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer and High FRa Expression

ctDNA as a Prognostic Marker in Intermediate-Risk Rhabdomyosarcoma

Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer in Survivors of Hodgkin Lymphoma